ADMA Biologics (ADMA) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Recursion Pharmaceuticals (RXRX) has outperformed ADMA Biologics (ADMA) over the past year, losing 18.4% versus a loss of 29.3%. Over five years, ADMA leads with a +839.1% price change compared with -77.6% for RXRX. ADMA Biologics is the larger company by market cap ($2.31 billion vs $2.12 billion), about 1.1 times the size, while Recursion Pharmaceuticals is growing revenue faster (+26.9% vs +19.6%).
ADMA Biologics converts more of its revenue into profit, with a net margin of 28.8% versus -863.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | RXRX |
|---|---|---|
| Share price | $10.33 | $3.95 |
| Market cap | $2.31B | $2.12B |
| 1-day change | +1.87% | -7.49% |
| YTD return | -43.37% | +4.40% |
| 1-year return | -29.34% | -18.36% |
| 5-year return | +839.09% | -77.57% |
| P/E ratio (TTM) | 14.76 | — |
| Forward P/E | 10.95 | — |
| EPS (TTM) | $0.70 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $510.17M | $74.68M |
| Revenue growth (YoY) | +19.63% | +26.92% |
| Net income (latest FY) | $146.93M | $-644.76M |
| Gross margin | 57.39% | 4.99% |
| Operating margin | 37.53% | -867.87% |
| Net margin | 28.80% | -863.35% |
| 52-week high | $20.46 | $7.18 |
| 52-week low | $7.21 | $2.77 |
| Distance from 52-week high | -49.51% | -44.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +64.57% | +82.78% |
| Average volume | 2.63M | 20.70M |
| Shares outstanding | 223.98M | 535.34M |
| Employees | 640 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RXRX has outperformed ADMA by 11.0 percentage points over the past year.
- ADMA Biologics is more profitable, keeping 28.8 cents of every revenue dollar as net income versus -863.4 cents for Recursion Pharmaceuticals.
- Recursion Pharmaceuticals grew revenue faster in its latest fiscal year (+26.92% vs +19.63%).
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
ADMA vs RXRX FAQ
Which is bigger, ADMA Biologics or Recursion Pharmaceuticals?
ADMA Biologics (ADMA) is larger, with a market capitalization of $2.31B compared with $2.12B for Recursion Pharmaceuticals (RXRX).
Which stock has performed better over the past year, ADMA or RXRX?
RXRX returned -18.36% over the past 12 months, compared with -29.34% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Recursion Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.